832-497-2220 [email protected]

Top-tier Chinese Pharmaceutical company profile: Chia Tai Tianqing Pharmaceutical Group

Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CTTO)

  • 2019 Sales Revenue: US$ 3.25 Billion
  • Number of Employees: 14,000
  • Founded: 1969


CTTQ is a multinational pharmaceutical company with integrated R&D, manufacturing, marketing, sales, and distribution capabilities. It was founded in 1969 and is headquartered in Lianyungang, Jiangsu Province, China.

CTTQ is the market leader in liver medicines in China. It was ranked 16th on the list of the “Top 100 Pharmaceutical Enterprises in China” in 2019. It was also among the top 5 most innovative Pharmaceutical Enterprises and the top 10 fastest-growing Pharmaceutical Manufacturers in China.


CTTQ has 2 R&D centers with a total of over 1500 employees. The company invests over 10% of its annual sales revenue in R&D every year. There are more than 250 projects in CTTQ’s product pipeline, in which State CategoryⅠinnovative drug projects make up more than 30%. By the end of 2019, they filed 1338 patents, including 1198 inventions. Among those filed, 424 patents were granted, comprising 338 inventions.

Products & Market

The company manufactures over 50 prescription medicines in 5 core therapeutic areas, including liver diseases, oncology, respiratory diseases, antibiotics, and diabetes. CTTO currently has 3 manufacturing plants focusing on FDF and API production, 1 overseas branch (CTTQ EU) in Barcelona, Spain, 1 business development office in San Diego, USA, and 4 joint labs (in Shanghai and Chengdu). The company has passed multiple EU and US GMP inspections, and Loratadine tablet was approved by BfArM in 2014. It is the first company to receive the new version of the Chinese GMP certificate.

CTTQ maintains 20+% annual revenue growth in every of the past 6 years. Its APIs and FDFs are sold to 30 countries in all major continents including the Americas, Europe, Asia, and Africa.

Overseas investment

In 2015, CTTQ and J&J entered into a license agreement for development and commercialization of one innovative drug for curative treatment of Hepatitis B. Another co-developed innovative drug, Anlotinib, was designated Orphan Drug status for treatment of ovarian cancer by the FDA. It has multiple ongoing clinical trials for other indications as well.

Other projects


Submit a Comment

Your email address will not be published.